We are live on
!
Find out more
Boston Trust Walden Portfolio holdings
AUM
$13.1B
Turnover
6.42%
1-Year Est. Return
24.63%
This Fund
S&P 500
This Quarter
Est. Return
+7.94%
1 Year Est. Return
+24.63%
3 Year Est. Return
+61.41%
5 Year Est. Return
+82.17%
10 Year Est. Return
+348.29%
AUM
$6.82B
AUM Growth
+$400M
(+6.2%)
Cap. Flow
-$64.1M
Cap. Flow
% of AUM
-0.94%
Top 10 Holdings %
Top 10 Hldgs %
17.87%
Holding
394
New
21
Increased
124
Reduced
197
Closed
10
Avg Time Held
3.1
years
Top 10 Avg Time Held
1.6
years
Top 20 Avg Time Held
2.1
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Becton Dickinson
BDX
|
+$14.8M |
| 2 |
Henry Schein
HSIC
|
+$14.3M |
| 3 |
Honeywell
HON
|
+$14.2M |
| 4 |
Pediatrix Medical
MD
|
+$13.5M |
| 5 |
Charles River Laboratories
CRL
|
+$13.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
BCR
CR Bard Inc.
BCR
|
+$62.1M |
| 2 |
CVS Health
CVS
|
+$18M |
| 3 |
Accendra Health
ACH
|
+$14.8M |
| 4 |
Ubiquiti
UI
|
+$13.1M |
| 5 |
Eagle Bancorp
EGBN
|
+$11.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 19.91% |
| 2 | Healthcare | 16.24% |
| 3 | Technology | 15.4% |
| 4 | Industrials | 13.98% |
| 5 | Consumer Discretionary | 8.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
126
Monro
MNRO
$442M
| $16.8M | 0.25% |
295,503
-7,743
| -3% | -$403K |
2017 Q2
2 quarters
|
|
127
Nordson
NDSN
$18B
| $16.7M | 0.24% |
114,107
+79
| +0.1% | +$10.2K |
2013 Q2
18 quarters
|
|
128
Haemonetics
HAE
$5.42B
| $16.7M | 0.24% |
287,036
-7,755
| -3% | -$408K |
2013 Q2
18 quarters
|
|
129
American States Water
AWR
$3.29B
| $16.4M | 0.24% |
283,860
-6,174
| -2% | -$338K |
2013 Q2
18 quarters
|
|
130
Charter Communications
CHTR
$12.7B
| $16.2M | 0.24% |
48,308
-1,322
| -3% | -$449K |
2016 Q2
6 quarters
|
|
131
Tootsie Roll Industries
TR
$2.88B
| $16M | 0.24% |
575,063
+6,726
| +1% | +$188K |
2015 Q4
8 quarters
|
|
132
IPG Photonics
IPGP
$3.08B
| $15.4M | 0.23% |
71,728
-17,078
| -19% | -$3.62M |
2013 Q2
18 quarters
|
|
133
Globus Medical
GMED
$10.4B
| $15M | 0.22% |
365,613
-9,728
| -3% | -$341K |
2016 Q2
6 quarters
|
|
134
EXL Service
EXLS
$5.97B
| $14.8M | 0.22% |
1,226,075
-30,075
| -2% | -$367K |
2015 Q2
10 quarters
|
|
135
Hawaiian Electric Industries
HE
$1.49B
| $14.5M | 0.21% |
402,331
-8,611
| -2% | -$312K |
2017 Q3
1 quarter
|
|
136
Brinker International
EAT
$8.52B
| $14.5M | 0.21% |
372,431
-21,223
| -5% | -$732K |
2016 Q2
6 quarters
|
|
137
McCormick & Company Non-Voting
MKC
$12.4B
| $14.4M | 0.21% |
283,254
+4,960
| +2% | +$247K |
2013 Q2
18 quarters
|
|
138
F5
FFIV
$25.1B
| $14.4M | 0.21% |
109,843
+23,359
| +27% | +$2.9M |
2013 Q2
18 quarters
|
|
139
Autoliv
ALV
$8.37B
| $14.4M | 0.21% |
157,423
-1,589
| -1% | -$144K |
2013 Q2
18 quarters
|
|
|
IPCC
140
DELISTED
Infinity Property & Casualty C
IPCC
| $14.3M | 0.21% |
134,810
-3,042
| -2% | -$309K |
2015 Q1
11 quarters
|
|
141
WEX
WEX
$6.18B
| $14.3M | 0.21% |
100,920
-2,385
| -2% | -$298K |
2013 Q2
18 quarters
|
|
142
Cognizant
CTSH
$29.1B
| $14.2M | 0.21% |
200,092
+3,035
| +2% | +$222K |
2013 Q2
18 quarters
|
|
143
Factset
FDS
$10.6B
| $14M | 0.21% |
72,717
+713
| +1% | +$137K |
2013 Q2
18 quarters
|
|
144
International Flavors & Fragrances
IFF
$23.1B
| $13.9M | 0.2% |
91,144
-690
| -0.8% | -$104K |
2013 Q2
18 quarters
|
|
145
AutoZone
AZO
$50.1B
| $13.9M | 0.2% |
19,548
-460
| -2% | -$294K |
2014 Q3
13 quarters
|
|
146
WaFd
WAFD
$2.17B
| $13.9M | 0.2% |
404,570
-9,868
| -2% | -$339K |
2016 Q4
4 quarters
|
|
|
147
Henry Schein
HSIC
$9.6B
| $13.8M | 0.2% |
251,007
+247,373
| +6,807% | +$14.3M |
2013 Q2
18 quarters
|
|
148
Anika Therapeutics
ANIK
$268M
| $13.5M | 0.2% |
250,148
-7,130
| -3% | -$395K |
2014 Q3
13 quarters
|
|
149
Minerals Technologies
MTX
$1.97B
| $13.4M | 0.2% |
195,162
-5,330
| -3% | -$379K |
2013 Q2
18 quarters
|
|
|
150
Charles River Laboratories
CRL
$14.4B
| $13.4M | 0.2% |
+122,536
| New | +$13.3M |
2017 Q4
0 quarters
|
|
Similar funds
Boston Trust Walden's Q4 2017 Portfolio in Review
As of Q4 2017, Boston Trust Walden held 394 positions worth $6.82B, up 6.2% from $6.42B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
Boston Trust Walden's Q4 2017 filing shows 21 new, 124 increased, 197 reduced and 10 closed positions. Its largest new stake was Charles River Laboratories: 122,536 shares worth $13.4M. The largest sale was CR Bard Inc., an estimated $62.1M.
By sector, the portfolio is most concentrated in Financials at 20% of assets, down from 20% a quarter earlier, followed by Healthcare and Technology.
- Boston Trust Walden's largest Q4 2017 buy was Charles River Laboratories: 122,536 shares worth $13.4M.
- Boston Trust Walden added most to Becton Dickinson in Q4 2017, an estimated $14.8M increase.
- Boston Trust Walden's biggest Q4 2017 reduction was CVS Health, cutting an estimated $18M.
- Boston Trust Walden fully exited CR Bard Inc. in Q4 2017, selling an estimated $62.1M.
- Boston Trust Walden's ten largest holdings make up 18% of its $6.82B portfolio in Q4 2017.
- Boston Trust Walden opened 21 new positions and closed 10 in Q4 2017.
- Boston Trust Walden's portfolio value rose 6.2% quarter-over-quarter to $6.82B.
Based on Boston Trust Walden's 13F filing for Q4 2017, filed 29 Jan 2018.